A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Trial details
- Registry ID
- NCT04374136
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)NCT04374136 | ALEC | Phase 3 | Terminated | 2025-09-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |